{
  "docId": "019de074-4969-72b8-bf99-262b9202adeb",
  "docSlug": "32d16c961ba3228c7796678a3b67d91c",
  "documentTitle": "ATAI | Investor Presentation Deck | 33 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-02-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 33,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 6,
  "notes": "The slide uses a dark sidebar for product specs and a white main area for trial design and results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-4969-72b8-bf99-262b9202adeb/19",
  "deckHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb",
  "deckJsonHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb.json",
  "deckAnchorHref": "/decks/019de074-4969-72b8-bf99-262b9202adeb#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.25,
        "w": 0.6,
        "x": 0.36,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "PCN-101 Phase 2a study design flow from screening to treatment to follow-up",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "88c562db-a9ab-4cbd-a53e-2e50d6d84600",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale... 1. Unless otherwise indicated... 2. Leal et al... 3. NCT05414422",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "06cb2faa-0ad8-4c54-929f-222784522dbf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.32,
        "x": 0.02,
        "y": 0.15
      },
      "kind": "list",
      "text": "OWNERSHIP 58.9% | PRODUCT Subcutaneous R-ketamine | PHARMACOLOGY Glutamatergic modulator | FEATURES Rapid-acting, non-dissociative | INDICATIONS TRD | STATUS Phase 2a results Jan 2023 | IP Issued methods | HIGHLIGHT Third party study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c78b9d0d-2206-47d6-82e7-d2fae5281831",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.6,
        "x": 0.36,
        "y": 0.6
      },
      "kind": "list",
      "text": "1. Study did not meet primary endpoint. 2. Mean change on MADRS was -15.3 vs -13.7. 3. Encouraging signals of efficacy. 4. Generally well-tolerated.",
      "attrs": null,
      "subkind": "numbered",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "949f9670-8cbd-4f00-a661-703cf8ea9076",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.15,
        "x": 0.02,
        "y": 0.07
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e5e2a55-4cb3-4aeb-a6e1-d5afac4179ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.06
      },
      "kind": "title",
      "text": "We’ve completed a Phase 2a study for PCN-101 and are evaluating next steps for the program",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d39f08a6-9fdc-41d8-aa7c-eb02379e4f37",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 33,
      "from": 3,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "720e63ac-a674-4bf4-8e46-acf9a0a900ae",
      "evidence": "The presentation follows the Golden Circle framework, starting with why atai Life Sciences is working on mental health disorders (p3) and presenting their solution and traction.",
      "position": 1,
      "objective": "Why is atai Life Sciences' solution important?",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}